The pharmaceutical company injected more than $2bn into life science businesses in 2017 and recorded 14 exits.
Denmark-based pharmaceutical firm Novo will intensify its life science investments after generating DKK56bn ($9.3bn) in income and investment returns from its non-Novo investment portfolio in 2017.
The corporate, which operates subsdiaries Novo Ventures and Novo Seeds, provided approximately $2.3bn in pre and post-IPO funding for companies in 2017, including investments in Genoa Pharmaceuticals, E-Scape Bio and Northsea Therapeutics.
Novo also provided funding for publicly-listed portfolio companies including drug development alliance Evotec, laboratory diagnostics services provider Synlab and medical product supplier ConvaTec,…
